Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

A randomized, double-blind, ascending multiple dose study in healthy volunteers and subjects with chronic rhinosinusitis with nasal polyps

Phase:

Phase 1

Details

Lead Sponsor:

Amgen